

DAY 1: SUNDAY, DECEMBER 5, 2021

OPENING SESSION

14:00 Registration

16:00 **Opening Remarks**
Raymond F. Schinazi
Emory University, USA

SESSION 1 **Epidemiology and prospects for global elimination: Viral hepatitis and chronic liver disease**

Chairs Lillian Lou Raymond F. Schinazi
The John C. Martin Foundation, USA Emory University, USA

16:15 **Plenary lecture: Global viral hepatitis epidemiology and prospects for global elimination**

Homie Razavi
CDA Foundation, USA

CME accredited

16:45 **HBV and chronic liver disease in Mexico**

Arturo Panduro Cerda
Hospital Civil de Guadalajara, Mexico

CME accredited

17:05 **HBV and chronic liver disease in South America**

Suzane K. Ono
University of São Paulo, Brazil

CME accredited

17:25 **Elimination of HBV and HCV on the African continent**

John Ward on behalf of: Manal EL-Sayed (Ain Shams University, Egypt)
The Task Force for Global Health, USA

CME accredited

17:45 **End of day 1 and welcome reception at Dolphin Pool Reception Area**

DAY 2: MONDAY, DECEMBER 6, 2021

Award Session

Chairs Anna Lok Mario Stevenson
University of Michigan Medical Center, USA University of Miami, USA

8:00 **Introduction and presentation of the William H. Prusoff HEP DART Lifetime Achievement Award**

Anna Lok Raymond F. Schinazi
University of Michigan Medical Center, USA Emory University, USA

8:20 **William H. Prusoff HEP DART Lifetime Achievement Award lecture: Elimination of viral Hepatitis A, B and C in the Alaska native population: Lessons learned for elimination strategies in isolated global populations**

Brian J. McMahon
Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, USA

CME accredited

SESSION 2 **Overview of viral hepatitis, co-infections and NASH**

Chairs Harry Janssen Stephan Urban
University of Toronto, Canada Heidelberg University, Germany

9:00 **Plenary lecture: Drugs and trials for HBV elimination**

Geoffrey Dusheiko
University College London, UK

CME accredited

9:30 **Molecular analysis and personalized medicine in NASH fibrosis and HCC**

Scott Friedman
Icahn School of Medicine at Mount Sinai, USA

CME accredited

9:50 **Break (20 min)**

10:10 **HBV co-infection with HIV or HCV**

Mark Sulkowski
Johns Hopkins University, USA

CME accredited

10:30 **Deltavirus infection in human and animal hosts**

Karim Majzoub
University of Montpellier, France

CME accredited

10:50 **Panel Discussion (15 min)**

Oral Abstract Session I

Chairs Douglas Dieterich Tarik Asselah
Icahn School of Medicine at Mount Sinai, USA Hôpital Beaujon, AP-HP, France

11:05 **Active site polymerase inhibitor nucleotides (ASPINs) are novel nucleos(t)ide analogues with a unique mechanism of action**

Robert Gish
Hepatitis B Foundation, USA

11:15 **Novel dimeric HBV capsid assembly modulators**

Leda Bassit
Emory University, USA

DAY 2: MONDAY, DECEMBER 6, 2021

- 11:25 **Targeting hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus *in vivo***
Paige Nemece
Precision BioSciences, USA
- 11:35 **Group picture (with social distancing)**
- 12:00 **Lunch (2 hr)**

SESSION 3 Hepatitis B basic science (Hepatitis B Foundation sponsored session)

- Chairs Tim Block Brian J. McMahon
Hepatitis B Foundation, USA Liver Disease and Hepatitis Program
Alaska Native Tribal Health Consortium, USA

- 14:20 **Update on Hepatitis B Foundation**
Tim Block
Hepatitis B Foundation, USA CME accredited
- 14:30 **HBV transcriptional regulation: New insights into the role of HBx**
Aleem Siddiqui
University of California San Diego, USA CME accredited
- 15:00 **Mechanistic insights into HBV cccDNA biogenesis**
Lei Wei
Princeton University, USA CME accredited
- 15:20 **New insights into HBV Integration**
Thomas Tu
University of Sydney, Australia CME accredited
- 15:40 **Afternoon break (20 min)**

SESSION 4 From bench to bedside: Clinical updates on hep B elimination

- Chairs Matteo Iannacone Jordan Feld
San Raffaele Scientific Institute, Italy University of Toronto, Canada

- 16:00 **Plenary lecture: What will it take to achieve HBV cure?**
Anna Lok
University of Michigan, USA CME accredited
- 16:30 **Nucleoside analog withdrawal: Is the glass half full or half empty?**
Harry Janssen
University of Toronto, Canada CME accredited
- 16:50 **Results from the Hepatitis B Research Network therapeutic trials**
Adrian Di Bisceglie
Saint Louis University, USA CME accredited
- 17:10 **Short break (10 min)**

Debate: Everyone who is HBV DNA positive should receive early treatment irrespective of disease stage

- Moderators Veronica Miller Mark Sulkowski
University of California Berkeley, USA Johns Hopkins University, USA

- 17:20 **The pro perspective**
Geoffrey Dusheiko
University College London, UK Harry Janssen
University of Toronto, Canada
- The con perspective**
Anna Lok
University of Michigan Medical Center, USA Brian J. McMahon
Liver Disease and Hepatitis Program
Alaska Native Tribal Health Consortium, USA

- 18:00 **End of day 2 and free evening**

DAY 3: TUESDAY, DECEMBER 7, 2021

SESSION 5 New advances in NASH, NAFLD, fibrosis, cirrhosis, HCC treatment

- Chairs John Ward Scott Friedman
The Task Force for Global Health, USA Icahn School of Medicine at Mount Sinai, USA

- 9:00 **Plenary lecture: NASH: Lessons from clinical trials and future perspectives**
Tarik Asselah
Hôpital Beaujon, AP-HP, France CME accredited
- 9:30 **Is NASH in HIV patients and HCC in HIV patients mostly due to undiagnosed HBV?**
Douglas Dieterich
Icahn School of Medicine at Mount Sinai, USA CME accredited
- 9:50 **Panel discussion (10 min)**

DAY 3: TUESDAY, DECEMBER 7, 2021

Oral Abstract Session II

10:00 **The liver liquid biopsy: External validation of serum protein models of liver steatosis, inflammation, hepatocyte ballooning, fibrosis, and at-risk NASH**
Leigh Alexander
SomaLogic, USA

10:10 **Break (30 min)**

SESSION 6 Advances in therapeutics for NASH, NAFLD, and liver disease

Chairs Veronica Miller Suzane K. Ono
University of California Berkeley, USA University of São Paulo, Brazil

Academic

10:40 **Efficacy of a higher daily aramchol dose on fibrosis improvement in the phase 3 open label part ARMOR study**
Carol Brosgart
University of California San Francisco, USA CME accredited

10:55 **Ileal bile acid transporter (IBAT) inhibitors and liver disease targets**
Saul Karpen
Emory University, USA CME accredited

Industry

11:10 **Long-term efficacy, safety and natural history comparisons of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus**
Douglas Mogul
Mirum Pharma, USA non-CME accredited

11:25 **Phase 3 development of resmetirom for the treatment of patients with NASH and significant liver fibrosis**
Becky Taub
Madrigal Pharmaceuticals, USA non-CME accredited

11:40 **Panel discussion (20 min)**

12:00 **Lunch and free afternoon (3 hr)**

15:00 **Poster reception**

16:30 **Review of poster presentations**
Adrian Di Bisceglie Andrea Cox
Saint Louis University, USA Johns Hopkins University, USA

SESSION 7 Industry session on advances in therapeutics for HBV (non-CME accredited)

Chairs Geoffrey Dusheiko Raymond F. Schinazi
University College London Emory University, USA

17:15 **Janssen's evolving strategy for development of novel combination therapies towards achieving functional cure for CHB**
Heather Davis
Janssen Infectious Disease and Vaccines (J&J), Belgium non-CME accredited

17:30 **Oligonucleotide-based strategies for targeting HBsAg: Understanding mechanisms and effects**
Andrew Vaillant
Replicor, Canada non-CME accredited

17:45 **Advances in combination therapy for the treatment of chronic hepatitis B**
Larry Blatt
Aligos Therapeutics, USA non-CME accredited

18:00 **Eliminating residual HBV replication – A critical gateway to cure**
William Delaney
Assembly Biosciences, USA non-CME accredited

18:15 **Progress toward an HBV cure combination therapy**
Michael Sofia
Arbutus BioPharma, USA non-CME accredited

18:30 **ATI-2173, a novel ASPIN, leads to prolonged off-treatment HBV viral suppression**
Douglas Mayers
Antios Therapeutics, USA non-CME accredited

18:45 **End of day 3 and free evening**

DAY 4: WEDNESDAY, DECEMBER 8, 2021

SESSION 8 Immunity, vaccines and transplantation in the context of viral hepatitis and chronic liver disease

Chairs Robert Gish Hepatitis B Foundation, USA Brent Korba Georgetown University Medical Center, USA

9:00 **Plenary lecture: Serum HBsAg clearance has minimal impact on CD8⁺ T cell responses**

Matteo Iannacone
San Raffaele Scientific Institute, Italy

CME accredited

9:30 **Impact of HCV DAA therapy on HCC incidence and mortality**

Nicole Rich
University of Texas Southwestern, USA

CME accredited

9:50 **Do we need direct immune modifying drugs to reach HBsAg loss in HBV?**

Adam Gehring
Toronto Centre for Liver Disease, Canada

CME accredited

10:10 **Long-acting injectables for viral hepatitis: Pipe dream or pathway to elimination?**

Mark Sulkowski
Johns Hopkins University, USA

CME accredited

10:30 **Roundtable discussion (15 min)**

10:45 **Break (20 min)**

SESSION 9 Liver disease and COVID-19

Chairs Carol Brosgart University of California San Francisco, USA Nicole Rich University of Texas Southwestern, USA

11:05 **Plenary lecture: COVID-19 threat and beyond**

Susan Weiss
University of Pennsylvania, USA

CME accredited

11:35 **Connection between COVID-19 and liver dysfunction**

Robert Gish
Hepatitis B Foundation, USA

CME accredited

Oral Abstract Session III

11:55 **SARS-CoV-2 infection in patients with concurrent chronic liver disease is associated with more severe disease presentation and significantly greater risk of severe pneumonia and respiratory failure**

Robert Wong
Stanford University, USA

12:05 **A fully-automated artificial intelligence algorithm in differentiating contrast-enhanced phases in liver computer tomography**

Suzane K. Ono
University of São Paulo, Brazil

12:15 **Lunch and break (2 hr, 45 min)**

SESSION 10 Illuminating new approaches to chronic liver disease

Chairs Adrian Di Bisceglie Saint Louis University, USA Adam Gehring Toronto Centre for Liver Disease, Canada

15:00 **Organ transplantation from HCV-positive donors to HCV-negative recipients: How short can we go?**

Jordan Feld
University of Toronto, Canada

CME accredited

15:20 **Updates from liver and HBV forums**

Veronica Miller
University of California Berkeley, USA

CME accredited

Oral Abstract Session IV

15:40 **Establishing a protocol for management and DAA treatment of HCV during pregnancy: Adherence to a co-located care protocol**

Tatyana Kushner
Icahn School of Medicine at Mount Sinai, USA

15:50 **Humanized NSG-PiZ mice support the study of hepatitis B virus antiviral therapies**

Keith Jerome
Fred Hutchinson Cancer Research Center, USA

16:00 **Break (20 min)**

Business discussion session (Non-CME accredited)

16:20 **NASH, HBV and coronavirus therapeutics: Looking back and looking forward**

Geoffrey Meacham Bank of America, USA David Witzke Avidity Partners, USA Skye Drynan Disruptive Therapeutics Acquisition, USA

16:50 **Discussion**

19:00 **Fiesta Nobel Mexicana at Beach Area**

DAY 5: THURSDAY, DECEMBER 9, 2021

SESSION 11 Non-ABC viral hepatitis: Epidemiology, pathogenesis and treatment

Chairs Susan Weiss
University of Pennsylvania, USA

Andrea Cox
Johns Hopkins University, USA

9:00 **Plenary lecture: Discovery and development of Bulevertide**

Stephan Urban
Heidelberg University, Germany

CME accredited

9:30 **Clinical development of Lonafarnib**

Jeffrey Glenn
Stanford University, USA

CME accredited

9:50 **Future cures for hepatitis delta virus**

Tarik Asselah
Hôpital Beaujon, AP-HP, France

CME accredited

10:30 **Roundtable discussion (15 min)**

10:45 **Break (15 min)**

Oral Abstract Session V

11:00 **Multi-pathway innate immunity antagonism by the hepatitis E virus ORF1 protein**

Robert LeDesma
Princeton University, USA

11:10 **Heterologous prime-boost immunotherapy circumvents tolerance and protects against hepatitis B and D co-infection and hepatitis D super-infection**

Richard Bethell
Karolinska Institutet, Sweden

11:20 **Leveraging machine learning to identify clinical attributes and social determinants of health associated with Hepatitis C virus to improve screening efficiency**

Annie Son
Gilead, USA

SESSION 12

Chairs Brian J. McMahon
Liver Disease and Hepatitis Program
Alaska Native Tribal Health Consortium, USA

Raymond F. Schinazi
Emory University, USA

11:30 **2021 & Beyond: Gaps in knowledge and roadmap to action**

Robert Gish
Hepatitis B Foundation, USA

Scott Friedman
Icahn School of Medicine at Mount Sinai, USA

12:00 **Closing remarks**

Raymond F. Schinazi
Emory University, USA

12:15 **Meeting adjourns**